BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen C, Zhao B, Liu L, Shih YT. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer 2018;124:364-73. [PMID: 28976559 DOI: 10.1002/cncr.31050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Atallah EL, Maegawa R, Latremouille-viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 2022;9. [DOI: 10.36469/001c.36975] [Reference Citation Analysis]
2 Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Kaye D, George D, Scales CD Jr, Baggett CD, Gross CP, Leapman MS, Wheeler SB. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Urology 2022:S0090-4295(22)00604-5. [PMID: 35878815 DOI: 10.1016/j.urology.2022.07.012] [Reference Citation Analysis]
3 Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. J Am Geriatr Soc 2022. [PMID: 35499667 DOI: 10.1111/jgs.17826] [Reference Citation Analysis]
4 de Germay S, Berdaï D, Noize P. Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives. Therapies 2022;77:229-240. [DOI: 10.1016/j.therap.2021.08.001] [Reference Citation Analysis]
5 Kaye DR, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Pollack CE, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Dinan MA. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.01.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Tan BK, Bee PC, Chua SS, Chen LC. Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review. Patient Prefer Adherence 2021;15:2563-75. [PMID: 34819724 DOI: 10.2147/PPA.S269355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Moss HA, Chen L, Hershman DL, Davidson B, Wright JD. Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecol Oncol 2021;163:262-8. [PMID: 34509297 DOI: 10.1016/j.ygyno.2021.08.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Cuneo A, Cavazzini F, Cavallari M, Foà R, Rigolin GM. Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. Cancer J 2021;27:320-7. [PMID: 34398559 DOI: 10.1097/PPO.0000000000000531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Heiney SP, Sorrell M, Sheng J, Adams SA, Nelson K, Nguyen LA, Edwards A, Wickersham KE. Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review. Am J Clin Oncol 2021;44:291-8. [PMID: 33867480 DOI: 10.1097/COC.0000000000000818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Talon B, Calip GS, Lee TA, Sharp LK, Patel P, Touchette DR. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. JCO Oncol Pract 2021;:OP2000967. [PMID: 33961496 DOI: 10.1200/OP.20.00967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mohanavelu P, Mutnick M, Mehra N, White B, Kudrimoti S, Hernandez Kluesner K, Chen X, Nguyen T, Horlander E, Thenot H, Kota V, Mitchell CS. Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Cancers (Basel) 2021;13:1643. [PMID: 33915952 DOI: 10.3390/cancers13071643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Muluneh B, Conti RM, Nguyen J, Cole A, Larson RA, Dusetzina SB. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-71913-5_7] [Reference Citation Analysis]
13 Kenzik KM, Bhatia R, Bhatia S. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status. JAMA Oncol 2020;6:542-6. [PMID: 31999305 DOI: 10.1001/jamaoncol.2019.6390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Pinto LC, Sales LDO, Azevedo TCDB, Moreira-nunes CA, Lemos JAR. Análise de mutações do domínio BCR-ABL quinase em pacientes com leucemia mielóide crônica refratários ao tratamento com mesilato de imatinibe. Rev Cienc Saude 2020;10:77-84. [DOI: 10.21876/rcshci.v10i4.994] [Reference Citation Analysis]
15 Clark SE, Marcum ZA, Radich JP, Bansal A. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia. J Oncol Pharm Pract 2020;:1078155220970616. [PMID: 33175653 DOI: 10.1177/1078155220970616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Seymour EK, Ruterbusch JJ, Winn AN, George JA, Beebe-Dimmer JL, Schiffer CA. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. Cancer 2021;127:93-102. [PMID: 33119175 DOI: 10.1002/cncr.33267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Vaughn JE, Shankaran V, Walter RB. Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come? Curr Hematol Malig Rep 2019;14:171-8. [PMID: 31079354 DOI: 10.1007/s11899-019-00510-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
18 Kirsch M, Montgomery JR, Hu HM, Englesbe M, Hallstrom B, Brummett CM, Fendrick AM, Waljee JF. Association between insurance cost-sharing subsidy and postoperative opioid prescription refills among Medicare patients. Surgery 2020;168:244-52. [PMID: 32505547 DOI: 10.1016/j.surg.2020.04.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Cole AL, Jazowski SA, Dusetzina SB. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia. Pharmacoepidemiol Drug Saf 2019;28:1529-33. [PMID: 31507005 DOI: 10.1002/pds.4893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Li P, Jahnke J, Pettit AR, Wong YN, Doshi JA. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open 2019;2:e195806. [PMID: 31199450 DOI: 10.1001/jamanetworkopen.2019.5806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Ganguly BB, Kadam NN. Genetics and tyrosine kinase inhibitors of chronic myeloid leukemia. Nucleus 2019;62:155-64. [DOI: 10.1007/s13237-019-00271-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer 2019;125:2570-8. [PMID: 30973642 DOI: 10.1002/cncr.32137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]